Diabetes Solutions

Accelerate your diabetes research

With the prevalence of diabetes expected to increase, you need one global partner to accelerate your diabetes research from discovery to post-market. At Q2 Solutions, we offer a complete range of diabetes drug development solutions including central, bioanalytical, ADME and genomic testing and biomarker services – plus support for companion diagnostic studies for personalized medicine.

Our lab experience includes testing services in support of clinical trials for insulins, GLP-1/glucagon dual-agonists, SGLT2 inhibitors, DPP-4 inhibitors (gliptins), combination therapies and more. See our infographic to learn more about our broad range of testing services and capabilities for diabetes studies.

We also participate in many proficiency and certification programs for endocrine testing, such as:
  • The National Glycohemoglobin Standardization Program (NGSP)
  • CDC Lipid Standardization Program
  • CAP Proficiency Scheme

Our industry renowned scientific experts are here to help you navigate today’s increasingly complex drug development programs. Contact us today to learn how we can advance your diabetes product development program.
Q2 Solutions Central Laboratory Services

Optimized logistics, deeper science, better insights

Q2 Solutions Genomic Laboratory Services

Genomic Know-How® for your drug development needs

Bioanalytical & ADME Laboratory Services

Accelerate and enhance your discovery, preclinical and clinical programs

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Q2 Solutions Company Brochure

Learn about what we do and our commitment to innovation

Read More